RT Journal Article
SR Electronic
T1 Single Prime hAd5 Spike (S) + Nucleocapsid (N) Dual Antigen Vaccination of Healthy Volunteers Induces a Ten-Fold Increase in Mean S- and N- T-Cell Responses Equivalent to T-Cell Responses from Patients Previously Infected with SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.05.21254940
DO 10.1101/2021.04.05.21254940
A1 Peter Sieling
A1 Thomas King
A1 Raymond Wong
A1 Andy Nguyen
A1 Kamil Wnuk
A1 Elizabeth Gabitzsch
A1 Adrian Rice
A1 Helty Adisetiyo
A1 Melanie Hermreck
A1 Mohit Verma
A1 Lise Zakin
A1 Annie Shin
A1 Brett Morimoto
A1 Wendy Higashide
A1 Kyle Dinkins
A1 Joseph Balint
A1 Victor Peykov
A1 Justin Taft
A1 Roosheel Patel
A1 Sofija Buta
A1 Marta Martin-Fernandez
A1 Dusan Bogunovic
A1 Patricia Spilman
A1 Lennie Sender
A1 Sandeep Reddy
A1 Philip Robinson
A1 Shahrooz Rabizadeh
A1 Kayvan Niazi
A1 Patrick Soon-Shiong
YR 2021
UL http://medrxiv.org/content/early/2021/04/07/2021.04.05.21254940.abstract
AB In response to the need for a safe, efficacious vaccine that provides broad immune protection against SARS-CoV-2 infection, we have developed a dual-antigen COVID-19 vaccine. The vaccine delivers both the viral spike (S) protein modified to increase cell-surface expression (S-Fusion) and the viral nucleocapsid (N) protein with an Enhanced T-cell Stimulation Domain (N-ETSD) to enhance MHC class I and II presentation and T-cell responses. The vaccine antigens are delivered using a human adenovirus serotype 5 (hAd5) platform with E1, E2b, and E3 regions deleted that has been shown in previous cancer vaccine studies to be effective in the presence of pre-existing hAd5 immunity. Here, we demonstrate the hAd5 S-Fusion + N-ETSD (hAd5 S + N) vaccine antigens when expressed by dendritic cells (DCs) of previously SARS-CoV-2-infected patients elicit Th1 dominant activation of autologous patient T cells, indicating the vaccine antigens have the potential for generating immune responses in patients previously infected or vaccinated. We further demonstrate that participants in our open-label Phase 1b study of the dual-antigen hAd5 S + N vaccine generate Th1 dominant S- and N-specific T cells after a single prime subcutaneous injection and that the magnitude of these responses were comparable to those seen for T cells from previously infected patients. We further present our in silico prediction of T-cell epitope HLA binding for both the first-wave SARS-CoV-2 ‘A’ strain and the K417N, E484K, and N501Y S as well as the T201I N variants that suggests T-cell responses to the hAd5 S + N vaccine will retain efficacy against these variants. These findings that the dual-antigen hAd5 S + N vaccine elicits SARS-CoV-2-relevant T-cell responses and that such cell-mediated protection is likely to be sustained against emerging variants supports the testing of this vaccine as a universal booster that would enhance and broaden existing immune protection conferred by currently approved S-based vaccines.Competing Interest StatementAll authors with an ImmunityBio, Inc. or NantKwest affiliation contributed to the conception, design, generation or testing of the vaccine described, which may become a commercial productClinical TrialNCT04591717Clinical Protocols https://www.clinicaltrials.gov/ct2/show/NCT04591717?term=QUILT&cond=COVID-19&draw=2&rank=2 Funding StatementFunded by ImmunityBio, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Western IRB for the Chan Soon-Shiong Institute for Medicine (CSSIFM) and the Hoag Hospital Providence IRB at Hoag Hospital Newport BeachAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are reported in the manuscript